- Home
- EVAX vs LEXX Comparison
EVAX vs LEXX Comparison
Compare EVAX & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- LEXX
- Stock Information
- Founded
- EVAX 2008
- LEXX 2004
- Country
- EVAX Denmark
- LEXX Canada
- Employees
- EVAX N/A
- LEXX N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- LEXX Health Care
- Exchange
- EVAX Nasdaq
- LEXX Nasdaq
- Market Cap
- EVAX 17.8M
- LEXX 16.5M
- IPO Year
- EVAX 2021
- LEXX N/A
- Fundamental
- Price
- EVAX $2.94
- LEXX $1.19
- Analyst Decision
- EVAX Strong Buy
- LEXX Strong Buy
- Analyst Count
- EVAX 2
- LEXX 1
- Target Price
- EVAX $10.00
- LEXX $4.00
- AVG Volume (30 Days)
- EVAX 88.6K
- LEXX 186.1K
- Earning Date
- EVAX 10-30-2025
- LEXX 07-14-2025
- Dividend Yield
- EVAX N/A
- LEXX N/A
- EPS Growth
- EVAX N/A
- LEXX N/A
- EPS
- EVAX N/A
- LEXX N/A
- Revenue
- EVAX $3,176,000.00
- LEXX $615,923.00
- Revenue This Year
- EVAX N/A
- LEXX $46.98
- Revenue Next Year
- EVAX N/A
- LEXX $17.26
- P/E Ratio
- EVAX N/A
- LEXX N/A
- Revenue Growth
- EVAX 1042.45
- LEXX 49.85
- 52 Week Low
- EVAX $1.20
- LEXX $0.77
- 52 Week High
- EVAX $17.20
- LEXX $3.72
- Technical
- Relative Strength Index (RSI)
- EVAX 52.59
- LEXX 71.37
- Support Level
- EVAX $2.71
- LEXX $0.98
- Resistance Level
- EVAX $3.04
- LEXX $1.07
- Average True Range (ATR)
- EVAX 0.19
- LEXX 0.10
- MACD
- EVAX -0.02
- LEXX 0.03
- Stochastic Oscillator
- EVAX 57.53
- LEXX 72.01
About EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.